Clinical Trials Logo

Citation(s)

  •   Altman DG
    How large a sample? Statistics in Practice. London, UK: British Medical Association 1982.
  •   Ascher B, Klap P, Marion MH, Chanteloub F
    [Botulinum toxin in the treatment of frontoglabellar and periorbital wrinkles. An initial study]. Ann Chir Plast Esthet. 1995 Feb;40(1):67-76. French.
  •   Ascher B
    Facial rejuvenation by non-endoscopic lifting and botulinum toxin injection. Les Cahiers D'Ophthalmologie 2000;45:25-31.
  •   Blitzer A, Brin MF, Keen MS, Aviv JE
    Botulinum toxin for the treatment of hyperfunctional lines of the face. Arch Otolaryngol Head Neck Surg. 1993 Sep;119(9):1018-22.
  •   Carruthers JA, Lowe NJ, Menter MA, Gibson J, Nordquist M, Mordaunt J, Walker P, Eadie N; BOTOX Glabellar Lines I Study Group
    A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol. 2002 Jun;46(6):840-9.
  •   Carruthers JD, Carruthers JA
    Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol. 1992 Jan;18(1):17-21.
  •   Elson ML
    Evaluation and treatment of the aging face. In: Evaluation and Treatment of the Aging Face. Elson MD, ed. Springer-Verlag, New York, 1995, 1-9.
  •   Erian A, Ionescu NE
    Combination treatment of glabellar rhytids. Int J Cosmetic Surg 1999;7(1):14-17.
  •   Fagien S
    Botox for the treatment of dynamic and hyperkinetic facial lines and furrows: adjunctive use in facial aesthetic surgery. Plast Reconstr Surg. 1999 Feb;103(2):701-13.
  •   Feller G, Bayerl C, Jung E, Rzany B
    Treatment of dynamic facial wrinkles with botulinum toxin type A (Dysport®)—a pilot study. Akt Deramtol 2000;26:65-9.
  •   Foster JA, Barnhorst D, Papay F, Oh PM, Wulc AE
    The use of botulinum A toxin to ameliorate facial kinetic frown lines. Ophthalmology. 1996 Apr;103(4):618-22.
  •   Guerrissi J, Sarkissian P
    Local injection into mimetic muscles of botulinum toxin A for the treatment of facial lines. Ann Plast Surg. 1997 Nov;39(5):447-53.
  •   Guyuron B, Huddleston SW
    Aesthetic indications for botulinum toxin injection. Plast Reconstr Surg. 1994 Apr;93(5):913-8.
  •   Kim EJ, Ramirez AL, Reeck JB, Maas CS
    The role of botulinum toxin type B (Myobloc) in the treatment of hyperkinetic facial lines. Plast Reconstr Surg. 2003 Oct;112(5 Suppl):88S-93S; discussion 94S-97S.
  •   Le Louarn C
    [Botulinum toxin and facial wrinkles: a new injection procedure]. Ann Chir Plast Esthet. 1998 Oct;43(5):526-33. French.
  •   Lowe NJ
    Botulinum toxin type A for facial rejuvenation. United States and United Kingdom perspectives. Dermatol Surg. 1998 Nov;24(11):1216-8. Review.
  •   McLarty JW, Levine RJ
    How many subjects are required for a study? IRB. 1987 Sep-Oct;9(5):1-3.
  •   Olver JM
    Botulinum toxin A treatment of overactive corrugator supercilii in thyroid eye disease. Br J Ophthalmol. 1998 May;82(5):528-33.
  •   Ramirez AL, Reeck J, Maas CS
    Botulinum toxin type B (MyoBloc) in the management of hyperkinetic facial lines. Otolaryngol Head Neck Surg. 2002 May;126(5):459-67.

A Double Blinded Randomized Controlled Trial to Compare the Efficacy, Time to Onset, and Duration of Two Botulinum Type A Exotoxins (Onabotulinum Toxin A and Abobotulinum Toxin A) in the Treatment of "Crow's Feet."

Details for clinical trial NCT01529788